secwatch.observer — SEC 8-K summary
======================================

Issuer:     Candel Therapeutics, Inc. (CADL)
CIK:        0001841387
Form:       8-K
Filed at:   2023-06-08T23:59:59+00:00
Accession:  0000950170-23-026913
Event type: leadership
Sentiment:  neutral
Materiality: 0.35
Item codes: 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Candel Therapeutics (CADL) appoints Nicoletta Loggia, PhD, RPh to board effective June 7, 2023
--------------------------------------------------------------------------------

- Board size increased from 9 to 10; Dr. Loggia appointed as Class III director with term expiring at 2024 annual meeting.
- She receives option for 28,480 shares vesting over 3 years plus standard non-employee director cash compensation.
- Dr. Loggia is CTO at Orchard Therapeutics, formerly Global Head of Cell & Gene Therapies at Novartis, with 20+ years experience.
- Appointment adds manufacturing expertise as company approaches phase 3 pivotal readout in localized prostate cancer.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1841387/000095017023026913/0000950170-23-026913-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1841387/000095017023026913/cadl-20230605.htm
  HTML page:      https://secwatch.observer/filing/0000950170-23-026913

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer